Business
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":"PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug (RLD) Alinia®. \"The market launch of Nitazoxanide Tablets, another niche limited competition product, underscores our purpose of ‘Serving Patients, Improving Lives’,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. \"We share ANI’s commitment to providing affordable, high-quality medicines for the patients who depend on them and are pleased to partner on the launch of this limited competition product,” stated Dr. Jagadeesh Rangisetty, Chief Executive Officer of Biophore. U.S. annual sales for Nitazoxanide Tablets total approximately $36.1 million, based on December 2024 moving annual total (MAT) IQVIA data. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives\" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com. About Biophore India Pharmaceuticals Pvt. Ltd.Biophore, an established pharmaceutical company, is engaged in the development and manufacturing of niche, high quality pharmaceutical products for the generic industry. Since its inception in 2007, Biophore has emerged as a trusted partner for niche and complex products in the generic industry across US, Europe and other regulated markets. For more information, please visit our website, http://www.biophore.com/. Forward-Looking StatementsThis press release contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statement...